Search Results

OSE Immunotherapeutics Provides Business and Corporate Update Three pharmaceutical agreements signed during the last three months.

OSE Immunotherapeutics Announces Publication of Preclinical Efficacy Results with Lusvertikimab in Acute Lymphoblastic Leukemia in the Journal ‘Blood’

OSE Immunotherapeutics SA, announced that the Company has entered into a commercial and revenue sharing agreement with leading global cancer center.

OSE Immunotherapeutics SA announced that all the resolutions submitted to a vote at the Combined General Shareholders’ Meeting were approved as proposed by OSE Immunotherapeutics’ Board of Directors.

OSE Immunotherapeutics SA and Boehringer Ingelheim announced a major expansion of their partnership.

OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) today announced that the Hart-Scott-Rodino waiting period has expired with respect to its global license with AbbVie to develop OSE-230, a monoclonal antibody designed to resolve chronic and severe inflammation, currently in the pre-clinical development stage.

OSE Immunotherapeutics joins key opinion leaders Dr Stephen Liu, associate professor and director of Thoracic Oncology at Georgetown University Lombardi Comprehensive Cancer Center and Prof Benjamin Besse, medical oncologist and director of clinical research at the Gustave Roussy Institute, to discuss the current unmet medical needs in lung cancer therapeutics and the development landscape of OSE Immunotherapeutics therapeutic cancer vaccine, Tedopi®.

OSE Immunotherapeutics SA, presented a poster on preclinical data on its mRNA therapeutic platform for the treatment of inflammatory and autoimmune disorders at the Federation of Clinical Immunology Societies annual meeting held in San Francisco.